TAKEDA PHARMACEUTIC-SP ADR (TAK) Fundamental Analysis & Valuation

NYSE:TAK • US8740602052

Current stock price

16.6 USD
-0.46 (-2.7%)
At close:
16.6 USD
0 (0%)
After Hours:

This TAK fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

8

1. TAK Profitability Analysis

1.1 Basic Checks

  • In the past year TAK was profitable.
  • In the past year TAK had a positive cash flow from operations.
  • TAK had positive earnings in each of the past 5 years.
  • In the past 5 years TAK always reported a positive cash flow from operatings.
TAK Yearly Net Income VS EBIT VS OCF VS FCFTAK Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 200B 400B 600B 800B 1T

1.2 Ratios

  • TAK has a Return On Assets of 0.73%. This is amongst the best in the industry. TAK outperforms 80.63% of its industry peers.
  • TAK's Return On Equity of 1.48% is amongst the best of the industry. TAK outperforms 82.20% of its industry peers.
  • The Return On Invested Capital of TAK (2.32%) is better than 79.58% of its industry peers.
  • Measured over the past 3 years, the Average Return On Invested Capital for TAK is significantly below the industry average of 13.11%.
Industry RankSector Rank
ROA 0.73%
ROE 1.48%
ROIC 2.32%
ROA(3y)1.33%
ROA(5y)1.73%
ROE(3y)2.84%
ROE(5y)3.97%
ROIC(3y)2.65%
ROIC(5y)2.57%
TAK Yearly ROA, ROE, ROICTAK Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2 4 6 8

1.3 Margins

  • The Profit Margin of TAK (2.53%) is better than 81.15% of its industry peers.
  • In the last couple of years the Profit Margin of TAK has grown nicely.
  • Looking at the Operating Margin, with a value of 10.76%, TAK belongs to the top of the industry, outperforming 82.72% of the companies in the same industry.
  • In the last couple of years the Operating Margin of TAK has grown nicely.
  • With a decent Gross Margin value of 65.33%, TAK is doing good in the industry, outperforming 71.73% of the companies in the same industry.
  • In the last couple of years the Gross Margin of TAK has remained more or less at the same level.
Industry RankSector Rank
OM 10.76%
PM (TTM) 2.53%
GM 65.33%
OM growth 3Y-7.47%
OM growth 5Y6.82%
PM growth 3Y-28.5%
PM growth 5Y11.87%
GM growth 3Y-1.71%
GM growth 5Y-0.42%
TAK Yearly Profit, Operating, Gross MarginsTAK Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 20 40 60

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

3

2. TAK Health Analysis

2.1 Basic Checks

  • With a Return on Invested Capital (ROIC) just above the Cost of Capital (WACC), TAK is creating some value.
  • The number of shares outstanding for TAK has been increased compared to 1 year ago.
  • TAK has more shares outstanding than it did 5 years ago.
  • The debt/assets ratio for TAK has been reduced compared to a year ago.
TAK Yearly Shares OutstandingTAK Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 1B 2B 3B
TAK Yearly Total Debt VS Total AssetsTAK Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 5T 10T 15T

2.2 Solvency

  • TAK has an Altman-Z score of 1.19. This is a bad value and indicates that TAK is not financially healthy and even has some risk of bankruptcy.
  • Looking at the Altman-Z score, with a value of 1.19, TAK is in line with its industry, outperforming 52.88% of the companies in the same industry.
  • TAK has a debt to FCF ratio of 6.48. This is a slightly negative value and a sign of low solvency as TAK would need 6.48 years to pay back of all of its debts.
  • TAK's Debt to FCF ratio of 6.48 is amongst the best of the industry. TAK outperforms 81.68% of its industry peers.
  • TAK has a Debt/Equity ratio of 0.56. This is a neutral value indicating TAK is somewhat dependend on debt financing.
  • TAK's Debt to Equity ratio of 0.56 is on the low side compared to the rest of the industry. TAK is outperformed by 67.54% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.56
Debt/FCF 6.48
Altman-Z 1.19
ROIC/WACC1.42
WACC1.63%
TAK Yearly LT Debt VS Equity VS FCFTAK Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 2T 4T 6T

2.3 Liquidity

  • TAK has a Current Ratio of 1.19. This is a normal value and indicates that TAK is financially healthy and should not expect problems in meeting its short term obligations.
  • TAK has a Current ratio of 1.19. This is amonst the worse of the industry: TAK underperforms 81.68% of its industry peers.
  • A Quick Ratio of 0.65 indicates that TAK may have some problems paying its short term obligations.
  • With a Quick ratio value of 0.65, TAK is not doing good in the industry: 88.48% of the companies in the same industry are doing better.
Industry RankSector Rank
Current Ratio 1.19
Quick Ratio 0.65
TAK Yearly Current Assets VS Current LiabilitesTAK Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 500B 1T 1.5T 2T 2.5T

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

4

3. TAK Growth Analysis

3.1 Past

  • TAK shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -45.17%.
  • The Earnings Per Share has been growing by 19.20% on average over the past years. This is quite good.
  • The Revenue has decreased by -2.50% in the past year.
  • Measured over the past years, TAK shows a small growth in Revenue. The Revenue has been growing by 6.84% on average per year.
EPS 1Y (TTM)-45.17%
EPS 3Y-22.57%
EPS 5Y19.2%
EPS Q2Q%341.77%
Revenue 1Y (TTM)-2.5%
Revenue growth 3Y8.68%
Revenue growth 5Y6.84%
Sales Q2Q%4.16%

3.2 Future

  • The Earnings Per Share is expected to grow by 44.51% on average over the next years. This is a very strong growth
  • The Revenue is expected to grow by 0.47% on average over the next years.
EPS Next Y77.07%
EPS Next 2Y62.14%
EPS Next 3Y44.51%
EPS Next 5YN/A
Revenue Next Year-1.08%
Revenue Next 2Y0.06%
Revenue Next 3Y0.47%
Revenue Next 5YN/A

3.3 Evolution

  • When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
  • When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
TAK Yearly Revenue VS EstimatesTAK Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 1T 2T 3T 4T
TAK Yearly EPS VS EstimatesTAK Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 0 50 -50 100

More info and screens

Find the best growth stocksShow best growing peers

6

4. TAK Valuation Analysis

4.1 Price/Earnings Ratio

  • A Price/Earnings ratio of 72.17 indicates a quite expensive valuation of TAK.
  • 78.01% of the companies in the same industry are more expensive than TAK, based on the Price/Earnings ratio.
  • TAK is valuated expensively when we compare the Price/Earnings ratio to 27.79, which is the current average of the S&P500 Index.
  • A Price/Forward Earnings ratio of 29.40 indicates a quite expensive valuation of TAK.
  • Compared to the rest of the industry, the Price/Forward Earnings ratio of TAK indicates a somewhat cheap valuation: TAK is cheaper than 74.87% of the companies listed in the same industry.
  • When comparing the Price/Forward Earnings ratio of TAK to the average of the S&P500 Index (38.88), we can say TAK is valued slightly cheaper.
Industry RankSector Rank
PE 72.17
Fwd PE 29.4
TAK Price Earnings VS Forward Price EarningsTAK Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 20 40 60

4.2 Price Multiples

  • Based on the Enterprise Value to EBITDA ratio, TAK is valued cheaper than 87.43% of the companies in the same industry.
  • Based on the Price/Free Cash Flow ratio, TAK is valued cheaply inside the industry as 88.48% of the companies are valued more expensively.
Industry RankSector Rank
P/FCF 11.14
EV/EBITDA 10.23
TAK Per share dataTAK EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 5 10 15

4.3 Compensation for Growth

  • The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
  • The excellent profitability rating of TAK may justify a higher PE ratio.
  • TAK's earnings are expected to grow with 44.51% in the coming years. This may justify a more expensive valuation.
PEG (NY)0.94
PEG (5Y)3.76
EPS Next 2Y62.14%
EPS Next 3Y44.51%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

6

5. TAK Dividend Analysis

5.1 Amount

  • TAK has a Yearly Dividend Yield of 3.58%. Purely for dividend investing, there may be better candidates out there.
  • TAK's Dividend Yield is rather good when compared to the industry average which is at 0.68. TAK pays more dividend than 95.81% of the companies in the same industry.
  • TAK's Dividend Yield is rather good when compared to the S&P500 average which is at 1.81.
Industry RankSector Rank
Dividend Yield 3.58%

5.2 History

  • The dividend of TAK has a limited annual growth rate of 1.18%.
  • TAK has been paying a dividend for at least 10 years, so it has a reliable track record.
  • TAK has not decreased its dividend in the last 3 years.
Dividend Growth(5Y)1.18%
Div Incr Years3
Div Non Decr Years4
TAK Yearly Dividends per shareTAK Yearly Dividends per shareYearly Dividends per share 2018 2019 2020 2021 2022 2023 2024 2025 2026 50 100 150

5.3 Sustainability

  • TAK pays out 277.04% of its income as dividend. This is not a sustainable payout ratio.
  • The dividend of TAK is growing, but earnings are growing more, so the dividend growth is sustainable.
DP277.04%
EPS Next 2Y62.14%
EPS Next 3Y44.51%
TAK Yearly Income VS Free CF VS DividendTAK Yearly Income VS Free CF VS DividendYearly Income VS Free CF VS Dividend 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 200B 400B 600B 800B
TAK Dividend Payout.TAK Dividend Payout, showing the Payout Ratio.TAK Dividend Payout.PayoutRetained Earnings

More info and screens

Find the best dividend stocksShow peers with best dividend

TAK Fundamentals: All Metrics, Ratios and Statistics

TAKEDA PHARMACEUTIC-SP ADR

NYSE:TAK (4/22/2026, 8:04:00 PM)

After market: 16.6 0 (0%)

16.6

-0.46 (-2.7%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)01-30
Earnings (Next)05-13
Inst Owners48.8%
Inst Owner Change-0.03%
Ins Owners0%
Ins Owner Change0%
Market Cap52.44B
Revenue(TTM)4.46T
Net Income(TTM)112.93B
Analysts74.74
Price Target20.07 (20.9%)
Short Float %0.22%
Short Ratio2.34
Dividend
Industry RankSector Rank
Dividend Yield 3.58%
Yearly Dividend0.6
Dividend Growth(5Y)1.18%
DP277.04%
Div Incr Years3
Div Non Decr Years4
Ex-Date03-30
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-15.65%
Min EPS beat(2)-121.92%
Max EPS beat(2)90.61%
EPS beat(4)2
Avg EPS beat(4)-2.37%
Min EPS beat(4)-121.92%
Max EPS beat(4)90.61%
EPS beat(8)4
Avg EPS beat(8)-37%
EPS beat(12)6
Avg EPS beat(12)-26.29%
EPS beat(16)8
Avg EPS beat(16)-33.22%
Revenue beat(2)1
Avg Revenue beat(2)-2.91%
Min Revenue beat(2)-6.04%
Max Revenue beat(2)0.21%
Revenue beat(4)1
Avg Revenue beat(4)-3.67%
Min Revenue beat(4)-6.76%
Max Revenue beat(4)0.21%
Revenue beat(8)4
Avg Revenue beat(8)1.91%
Revenue beat(12)7
Avg Revenue beat(12)2.79%
Revenue beat(16)11
Avg Revenue beat(16)3.3%
PT rev (1m)10.43%
PT rev (3m)21.52%
EPS NQ rev (1m)-1.09%
EPS NQ rev (3m)-26.93%
EPS NY rev (1m)1.43%
EPS NY rev (3m)-3.5%
Revenue NQ rev (1m)0.22%
Revenue NQ rev (3m)3.2%
Revenue NY rev (1m)0.12%
Revenue NY rev (3m)0.7%
Valuation
Industry RankSector Rank
PE 72.17
Fwd PE 29.4
P/S 1.87
P/FCF 11.14
P/OCF 7.01
P/B 1.09
P/tB N/A
EV/EBITDA 10.23
EPS(TTM)0.23
EY1.39%
EPS(NY)0.56
Fwd EY3.4%
FCF(TTM)1.49
FCFY8.98%
OCF(TTM)2.37
OCFY14.26%
SpS8.89
BVpS15.21
TBVpS-3.24
PEG (NY)0.94
PEG (5Y)3.76
Graham Number8.87252 (-46.55%)
Profitability
Industry RankSector Rank
ROA 0.73%
ROE 1.48%
ROCE 3.75%
ROIC 2.32%
ROICexc 2.47%
ROICexgc 10.72%
OM 10.76%
PM (TTM) 2.53%
GM 65.33%
FCFM 16.77%
ROA(3y)1.33%
ROA(5y)1.73%
ROE(3y)2.84%
ROE(5y)3.97%
ROIC(3y)2.65%
ROIC(5y)2.57%
ROICexc(3y)2.79%
ROICexc(5y)2.75%
ROICexgc(3y)14.77%
ROICexgc(5y)14.24%
ROCE(3y)4.3%
ROCE(5y)4.17%
ROICexgc growth 3Y-5.18%
ROICexgc growth 5Y8.79%
ROICexc growth 3Y-2.83%
ROICexc growth 5Y11.44%
OM growth 3Y-7.47%
OM growth 5Y6.82%
PM growth 3Y-28.5%
PM growth 5Y11.87%
GM growth 3Y-1.71%
GM growth 5Y-0.42%
F-Score5
Asset Turnover0.29
Health
Industry RankSector Rank
Debt/Equity 0.56
Debt/FCF 6.48
Debt/EBITDA 3.48
Cap/Depr 58.95%
Cap/Sales 9.86%
Interest Coverage 4.11
Cash Conversion 96.87%
Profit Quality 663%
Current Ratio 1.19
Quick Ratio 0.65
Altman-Z 1.19
F-Score5
WACC1.63%
ROIC/WACC1.42
Cap/Depr(3y)69.03%
Cap/Depr(5y)56.25%
Cap/Sales(3y)11.53%
Cap/Sales(5y)9.44%
Profit Quality(3y)309.71%
Profit Quality(5y)308.48%
High Growth Momentum
Growth
EPS 1Y (TTM)-45.17%
EPS 3Y-22.57%
EPS 5Y19.2%
EPS Q2Q%341.77%
EPS Next Y77.07%
EPS Next 2Y62.14%
EPS Next 3Y44.51%
EPS Next 5YN/A
Revenue 1Y (TTM)-2.5%
Revenue growth 3Y8.68%
Revenue growth 5Y6.84%
Sales Q2Q%4.16%
Revenue Next Year-1.08%
Revenue Next 2Y0.06%
Revenue Next 3Y0.47%
Revenue Next 5YN/A
EBIT growth 1Y0.22%
EBIT growth 3Y0.56%
EBIT growth 5Y14.13%
EBIT Next Year442.96%
EBIT Next 3Y77.92%
EBIT Next 5YN/A
FCF growth 1Y680.23%
FCF growth 3Y-8.86%
FCF growth 5Y9.4%
OCF growth 1Y62.56%
OCF growth 3Y-2%
OCF growth 5Y9.54%

TAKEDA PHARMACEUTIC-SP ADR / TAK Fundamental Analysis FAQ

What is the fundamental rating for TAK stock?

ChartMill assigns a fundamental rating of 5 / 10 to TAK.


What is the valuation status for TAK stock?

ChartMill assigns a valuation rating of 6 / 10 to TAKEDA PHARMACEUTIC-SP ADR (TAK). This can be considered as Fairly Valued.


How profitable is TAKEDA PHARMACEUTIC-SP ADR (TAK) stock?

TAKEDA PHARMACEUTIC-SP ADR (TAK) has a profitability rating of 8 / 10.


What is the earnings growth outlook for TAKEDA PHARMACEUTIC-SP ADR?

The Earnings per Share (EPS) of TAKEDA PHARMACEUTIC-SP ADR (TAK) is expected to grow by 77.07% in the next year.


Is the dividend of TAKEDA PHARMACEUTIC-SP ADR sustainable?

The dividend rating of TAKEDA PHARMACEUTIC-SP ADR (TAK) is 6 / 10 and the dividend payout ratio is 277.04%.